Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

AIDS

Volumn 12, Issue 15, 1998, Pages 2007-2015

  Schmit, Jean Claude ^a,b,g   Van Laethem, Kristel ^a   Ruiz, Lidia ^c   Hermans, Philippe ^d   Sprecher, Suzanne ^d   Sönnerborg, Anders ^e   Leal, Manuel ^f   Harrer, Thomas ^b,g   Clotet, Bonaventura ^e   Arendt, Vic ^b,g   Lissen, Eduardo ^f   Witvrouw, Myriam ^a   Desmyter, Jan ^a   De Clercq, Erik ^a   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Retrovirology Laboratory Luxembourg   (Luxembourg)

^c Retrovirology Laboratory IRSI Caixa   (Spain)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Viral Hepatitis and AIDS Study Group   (Spain)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Dideoxynucleoside analogues; HIV 1; Multiple drug resistance

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; DRUG RESISTANCE; EUROPE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RECOMBINANT;

EID: 7844241226     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00012     Document Type: Article

References (29)

1. Carpenter CCJ, Fishl MA, Hammer SM, et al.: Antiviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 277:1962-1969.
2. BHIVA Guidelines-Co-ordinating-Committee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
3. Schinazi RF, Larder BA, Mellors JW: Mutations in retroviral genes associated with drug resistance. Int Antivir News 1996, 4:95-107.
4. Shirasaka T, Yarchoan R, O'Brien MC, et al.: Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993, 90:562-566.
5. Shafer RW, Kozal MJ, Winters MA, et al.: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994, 169:722-729.
6. Maeda Y, Venzon DJ, Mitsuya H: Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998, 177:1207-1213.
7. Schmit J-C, Cogniaux J, Hermans P, et al.: Multiple drug resistance in nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996, 174:962-968.
8. Vandamme A-M, Vandooren S, Kok W: Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J Virol Methods 1995, 52:121-132.
9. Vandamme A-M, Witvrouw M, Pannecouque C, et al.: Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In Methods in Molecular Biology: Antiviral lesting. Edited by Schinazi RF. Tolowa, USA: The Humana Press; 1998 (in press).
10. Saitou N, Nei M: The neighbour-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-425.
11. Felsenstein J: PHYLIP-Phylogeny inference package (version 3.2). Cladistic 1989, 5:164-166.
12. Korber B, Myers G: Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Human Retrovir 1992, 8:1549-1560.
13. Kellam P, Larder BA: Recombinant virus assay: a rapid, phenotypic assay for assessement of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
14. Maschera B, Furfine L, Blair ED: Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995, 69:5431-5436.
15. Reed LJ, Muench H: A simple method of estimating fifty percent endpoints. Am J Hygiene 1938, 27:493-497.
16. Pauwels R, Balzarini J, Baba M, et al.: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988, 20:309-321.
17. Chou TC: Relationships between inhibition constants and fractional inhibitions in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types of mechanisms of inhibition. Mol Pharmacol 1974, 10:235-247.
18. Maeda Y, Ueno T, Kavlick MF, Shirasaka T, Yarchoan R, Mitsuya H. Emergence of multi-dideoxynucleoside-resistant HIV-1 in patients receiving long-term combination therapy with dideoxynucleosides. Fifth International Workshop on HIV Drug-Resistance. Whistler, Canada, 1996.
19. Shirasaka T, Kavlick MF, Ueno T, et al.: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
20. Shafer RW, Iversen AKN, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC: Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995, 172:70-78.
21. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
22. St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
23. Barber AM, Hizi A, Maizel JV, Hughes SH: HIV-1 reverse transcriptase: structure predictions for the polymerase domain. AIDS Res Human Retrovir 1990, 6:1061-1072.
24. Iversen AKN, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC: Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996, 70:1086-1090.
25. Van Rompay KKA, Greenier JL, Marthas ML, et al.: Zidovudine-resistant simian immunodeficiency virus with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother 1997, 47:278-283.
26. Vandamme AM, Schmit J-C, Witvrouw M, et al.: An HIV strain displayed partial reversal of phenotypic but not genotypic multinucleoside resistance after resistance selection with quinoxaline (HBY097). Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, Germany, 1997.
27. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
28. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
29. Pauwels R, Andries K, Debyser Z, et al.: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:1711-1715.